{"id":"hlcm051","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, HLCM051 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin, which are used to treat type 2 diabetes.","oneSentence":"HLCM051 is a small molecule targeting the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:26.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03807804","phase":"PHASE2","title":"Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Healios K.K.","startDate":"2019-01-01","conditions":"Respiratory Distress Syndrome, Adult","enrollment":35},{"nctId":"NCT02961504","phase":"PHASE2, PHASE3","title":"Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements","status":"COMPLETED","sponsor":"Healios K.K.","startDate":"2017-11-15","conditions":"Stroke, Acute","enrollment":206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"HLCM051","genericName":"HLCM051","companyName":"Healios K.K.","companyId":"healios-k-k","modality":"Biologic","firstApprovalDate":"","aiSummary":"HLCM051, also known as MultiStem, is being studied in a phase 2/3 clinical trial for its efficacy and safety in treating ischemic stroke. The trial is a placebo-controlled, double-blind study that also involves patients with acute respiratory distress syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}